Definium Therapeutics (DFTX) Net Cash Flow (2019 - 2026)

Definium Therapeutics (DFTX) has 7 years of Net Cash Flow data on file, last reported at $4.7 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $4.7 million, up 102.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $179.7 million (up 206.02% YoY), and the FY2025 annual result was -$15.9 million, down 109.13% from the prior year.
• Net Cash Flow eased to $4.7 million in Q1 2026 per DFTX's latest filing, from $237.9 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $237.9 million in Q4 2025 and troughed at -$190.9 million in Q1 2025.
• A 5-year average of $7.6 million and a median of -$12.6 million in 2023 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow soared 6656.87% in 2024, then sank 437.84% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$12.4 million in 2022, then slumped by 44.53% to -$18.0 million in 2023, then slipped by 19.89% to -$21.5 million in 2024, then jumped by 1204.15% to $237.9 million in 2025, then tumbled by 98.03% to $4.7 million in 2026.
• Business Quant data shows DFTX's Net Cash Flow at $4.7 million in Q1 2026, $237.9 million in Q4 2025, and -$13.4 million in Q3 2025.